Technology
Build around patent protected chemiluminescent enzyme substrates.
Build around patent protected chemiluminescent enzyme substrates.
The ENZYSYSTEM has only 4 components: blood sampling device (TAP in case of haemophilia), microfluidic cartridge (ENZYCARD), processor (ENZYPAD) and a mobile phone with the ENZY app. As it is the size of a small tablet, the ENZYSYSTEM consisting of an ENZYPAD and diease-specific multiparameter ENZYCARDS is easily portable and fits into a small backpack.
Each ENZYCARD contains reagents and appropriate controls to perform several coagulation tests in parallel on a single blood sample. The results have the same quality as if performed on a large instrument in a specialized laboratory and are available in real-time right next to the patient who can get the optimal therapy without any delay.
In order to find the cause of a bleed, in most cases it is necessary to determine several parameters simultaneously. As a single ENZYCARD can handle up to sixteen tests in parallel, there is ample space for multiple assays and corresponding controls.
The ENZYPAD will encrypt the data of the test results and transfer them via a Bluetooth connection to a mobile phone app, that will place the data in the cloud where anyone with the appropriate credentials can access them.
Chemiluminescent technology is a powerful tool for specific and sensitive detection of various biomarkers, including the proteins of blood coagulation, the core expertise of the company. In our chemiluminescent-based assays, the activity of blood coagulation and fibrinolysis enzymes is detected through the generation of light-emitting reaction products, rapidly and sensitively detected by optical sensors, enabling global and quantitative assays for blood coagulation monitoring. The technology can be however by applied much more broadly in collaboration with partners that have expertise in different fields.
Coagulation begins almost instantly after an injury to the blood vessel has damaged the lining of the blood vessel. The coagulation cascade is a complex system with multiple enzymatic reactions that should be monitored to prevent excessive bleeding in patients with chronic bleeding disorders (haemophilia A, von Willebrand disease, thrombotic thrombocytopenic purpura, and others). Patients receiving rebalancing or bypassing procoagulant therapy must frequently check specific clotting factor levels to ensure the treatment is effective and safe. A point-of-care platform would facilitate this routine and deliver faster diagnostics with reduced healthcare burden.
Enzyre's patented chemiluminescent-based assays requires enzyme-specific aminoluciferin substrates that will be cleaved by a specific enzyme. After cleavage, aminoluciferin is liberated and immediately captured by firefly luciferase and will emit photons in the presence of ATP and Magnesium salt. Enzyre has synthesized over 700 substrates ensuring specificity to blood coagulation enzymes. Examples of the technology are FVIII activity assay [1] and thrombin generation assay.
The method relies on the competition between two antigens, one of which is luciferase-labelled, for binding to a capture antibody. At the moment, this approach has been proven to be feasible for the vWF (von Willebrand Factor) antigen assay.
A chimeric protein substrate, engineered to contain specific cleavage sites, is embedded within the 3D matrix, mimicking physiological conditions. The principle is currently used for the detection of ADAMTS13 activity.
Enzyre is always looking for collaborations to expand use of its platform technologies. Interested parties are encouraged to contact us at info@enzyre.com.
Get involved
Enzyre BV
Transistorweg 5
6534-AT Nijmegen
The Netherlands
